论文部分内容阅读
目的 探讨细胞分化剂（ＣＤＡⅡ）治疗晚期恶性肿瘤的临床疗效。方法 ４５ 例晚期恶性肿瘤患者随机分成试验组（ＣＤＡⅡ治疗）２３ 例，对照组（不用ＣＤＡⅡ）２２ 例。试验组用ＣＤＡⅡ２００ｍ ｌ加林格氏液３００ｍ ｌ加维生素Ｃ５～１０ 克静滴，每天一次，连续２０～３０ 天为一疗程：或口服ＣＤＡⅡ胶囊６～８ 粒，每天３次，一个月为一疗程。对照组不用ＣＤＡⅡ。治疗期间每周查白细胞计数。治疗前、后进行Ｔ细胞亚群测试及测定肝、肾功能。结果 近期疗效，试验组与对照组分别为６０．９％ 、３１．８％ 。试验组白细胞计数治疗前、后无明显变化，对照组有不同程度下降。试组组治疗后Ｔ细胞亚群中ＣＤ＋３ 、ＣＤ＋４ 水平明显高于对照组（Ｐ＜ ０．０１）。结论 细胞分化剂具有较强的抑瘤作用，且能提高机体的细胞免疫功能，改善生活质量，无常规化疗药物的毒副作用，为晚期恶性肿瘤病人的综合治疗提供了一种新的手段。
Objective To investigate the clinical efficacy of cell differentiation agent (CDA-II) in the treatment of advanced malignant tumors. Methods Forty-five patients with advanced malignant tumor were randomly divided into experimental group (CDA-II treatment) of 23 cases and control group (without CDA-II) of 22 cases. The experimental group was treated with CDA-II 200ml Galinger 300ml plus vitamin C5-10g intravenously once a day for 20-30 days as a course of treatment: Oral CDA-II capsule 6-8 capsules, 3 times a day, One month is a course of treatment. The control group did not use CDA-II. White blood cell counts were checked weekly during treatment. Before and after treatment, T cell subsets were tested and liver and kidney functions were measured. Results The short-term efficacy was 60.9% and 31.8% in the test group and the control group, respectively. There was no significant change in the white blood cell count before and after the treatment in the test group, but the control group had different degrees of decline. After treatment, the levels of CD+3 and CD+4 in the T-cell subsets in the test group were significantly higher than those in the control group (P<0.01). Conclusion The cell differentiation agent has a strong anti-tumor effect, and can improve the body’s cellular immune function, improve the quality of life, no toxic side effects of conventional chemotherapy drugs, and provides a new means for the comprehensive treatment of advanced malignant tumor patients.